Schizophrenia With Positive And Negative Symptoms Therapeutics
1. Barhemsys patent expiration
Treatment: Prevention and treatment of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting; Prevention of post-operative nausea and vomiting
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12329740 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(12 years from now) | |
| US12194022 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(5 years from now) | |
| US12005042 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(12 years from now) | |
| US11357753 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(12 years from now) | |
| US9545426 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(5 years from now) | |
| US9889118 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(5 years from now) | |
| US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(8 years from now) | |
| US10525033 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 27 February, 2024
Market Authorisation Date: 26 February, 2020
Dosage: SOLUTION
More Information on Dosage
BARHEMSYS family patents
2. Fanapt patent expiration
Treatment: Indicated for the acute treatment of adults with schizophrenia; Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Method...
FANAPT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE39198 | VANDA PHARMS INC | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics |
Nov, 2016
(9 years ago) | |
| US9074254 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(5 years from now) | |
| US8586610 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Nov, 2027
(1 year, 9 months from now) | |
| US9138432 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Sep, 2025
(3 months ago) | |
| US8999638 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(4 years from now) | |
| US9074255 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(4 years from now) | |
| US9074256 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(5 years from now) | |
| US9157121 | VANDA PHARMS INC | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(4 years from now) | |
| US9072742 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(5 years from now) | |
| US8652776 | VANDA PHARMS INC | Prediction of QT prolongation based on SNP genotype |
Aug, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
| M(M-180) | May 26, 2019 |
| New Indication(I-939) | Apr 02, 2027 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Dosage: TABLET
How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage
FANAPT family patents